FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 42 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China MOST POPULAR FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC February 2, 2023 Cancer Survivor Kicked Out Of Bridal Party Cause She Refused To... August 29, 2019 El cáncer en mi comunidad: Ampliar el acceso a las pruebas... September 1, 2020 Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for... July 7, 2021 Load more HOT NEWS Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows Research with integrity – all the fun of the FAIR ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People Immune cell count could determine whether chemotherapy is required in oropharyngeal...
